តម្លៃភាគហ៊ុន និងព័ត៌មានអំពី Arbutus Biopharma Corp (ABUS)

ទំព័រដើមABUS • NASDAQ

Arbutus Biopharma Corp

4.26$

16 មីនា, 8:20:34 AM ម៉ោងសកល -4 · USD · NASDAQ · សេចក្ដីប្រកាសមិនទទួលខុសត្រូវ

ភាគហ៊ុនមូលបត្រដែលបានចុះបញ្ជីនៅ អាមេរិកមានទីស្នាក់ការកណ្ដាលនៅ អាមេរិក

បិទពីមុន

4.26$

ចន្លោះមួយឆ្នាំចុងក្រោយ

2.71$ - 5.10$

ដើមទុនទីផ្សារ

819.30 លាន USD

ទំហំជួញដូរមធ្យម

2.67 លាន

អនុបាត P/E

ទិន្នផលភាគលាភ

ការដោះដូរចម្បង

NASDAQ

ព័ត៌មានទីផ្សារ

GlobeNewswire

16 នាទីមុន

JFB (NASDAQ: JFB) Announces XTEND and Rayonix Execute

New to The Street Broadcasts Episode Featuring FreeCast (NASDAQ:CAST), KLED.AI, PetVivo (OTCQB:PETV), EmpowerLit, and BlackBarn NYC on Bloomberg Television - March 21 at 6:30 PM EST

Quipt Home Medical (NASDAQ: QIPT) delists common shares via Form 25

Trump has 15 days to end the Iran war or markets face a brutal April repricing — from oil to the S&P 500

Severe oil shock could drag S&P 500 down to 5,400, Goldman warns

Acadia Pharmaceuticals Rings the Opening Bell

ACAD

0.00%

អំពី

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia

CEO

William H. Collier

បានបង្កើតឡើង

2007

ការិយាល័យកណ្ដាល

Warminster Township, ផេនស៊ីលវ៉ានី
សហរដ្ឋអាមេរិក

តំបន់បណ្ដាញ

arbutusbio.com

បុគ្គលិក